Results 151 to 160 of about 144,202 (264)

Checking the Cox Proportional Hazards Model with Interval-Censored Data. [PDF]

J Am Stat Assoc
Xu Y, Zeng D, Lin DY.
europepmc   +1 more source

On estimation of P(Y < X) for inverse Pareto distribution based on progressively first failure censored data. [PDF]

PLoS One, 2023
Alharbi R, Garg R, Kumar I, Kumari A, Aldallal R.   +4 more
europepmc   +1 more source

Pharmacogenomic profiling of the efficacy of gemcitabine monotherapy in metastatic pancreatic cancer: Subgroup analysis of the GENESECT study

British Journal of Clinical Pharmacology, EarlyView.
Aim In the GENESECT study, no significant gemcitabine (GEM) metabolism‐related germline genetic polymorphisms (GPs) were identified because approximately 70% of patients received combination therapy with nab‐paclitaxel, which has metabolic pathways different from GEM.
Takashi Yokokawa, Daiki Tsuji, Masahiro Hatori, Kazuyoshi Kawakami, Masahiko Nakao, Takuya Yano, Yuichiro Arakawa, Keisuke Matsuo, Yasukata Ohashi, Masato Ozaka, Naoki Sasahira, Yasuhiko Sakata, Yuki Kogure, Shinya Tamaki, Atsushi Wada, Yusuke Taki, Wataru Suzuki, Kazuo Kobayashi, Hiroshi Ishii, Kunihiko Itoh, Masakazu Yamaguchi, Kenichi Suzuki   +21 more
wiley   +1 more source

Machine Learning Approach for Analyzing Mixed Case Interval Censored Data with a Cured Subgroup. [PDF]

Adv Stat Anal
Aselisewine W, Pal S.
europepmc   +1 more source

Pregnancy‐related effect on elexacaftor, tezacaftor and ivacaftor pharmacokinetics in women with cystic fibrosis

British Journal of Clinical Pharmacology, EarlyView.
Aim The number of pregnancies among women with cystic fibrosis (wwCF) has steadily increased over the past decade. However, the pharmacokinetics (PK) of elexacaftor–tezacaftor–ivacaftor (ETI) during gestation remains uncharacterized, despite its widespread use in this population.
Paulette Magnas, Naim Bouazza, Frantz Foissac, Saïk Urien, Léo Froelicher‐Bournaud, Gabrielle Lui, Victoria Guillemart, Nicolas Carlier, Jennifer Da Silva, Johanna Fesenbeckh, Reem Kanaan, Isabelle Honoré, Clémence Martin, Jean‐Marc Treluyer, Vassilis Tsatsaris, Pierre‐Régis Burgel, Sihem Benaboud   +16 more
wiley   +1 more source

Bayesian Estimation of Multicomponent Stress-Strength Model Using Progressively Censored Data from the Inverse Rayleigh Distribution. [PDF]

Entropy (Basel)
Yılmaz A.
europepmc   +1 more source

Utilization of immune checkpoint inhibitors for the treatment of cancer in Scotland, 2018–2024: A national retrospective cohort study

British Journal of Clinical Pharmacology, EarlyView.
Aims The aim of the study is to describe the use of immune checkpoint inhibitors (ICIs) for the treatment of cancer in Scotland. Methods The retrospective observational cohort study included patients aged 18 years or older who commenced treatment with an ICI in Scotland between 1 January 2018 and 31 December 2024.
Tanja Mueller, Christine Crearie, Liya Lu, Jiafeng Pan, Fraser N. Sneden, David Martin, Amanj Kurdi, Catherine S. Thomson, Julie Clarke, Marion Bennie   +9 more
wiley   +1 more source

Mean Cost and Cost-Effectiveness Ratios with Censored Data: a Tutorial and SAS^® Macros. [PDF]

Biostat Epidemiol
Poltavskiy E, Liu D, Chen S, Bang H, Zhao H.   +4 more
europepmc   +1 more source

Impact of parameter settings on the estimation of drug exposure with the individualized dispensing patterns method

British Journal of Clinical Pharmacology, EarlyView.
Aim To assess the impact of parameter settings when using the individualized dispensing patterns (IDP) method to estimate exposure duration from dispensing data. Methods We conducted a cohort study using a 2% representative sample of the French healthcare insurance database from 2013 to 2022.
Laëtitia Gosselin, Clara Lévy, Noémie Sève, Thierry Blanchon, Marianne Sarazin, Louise Rossignol, Maryse Lapeyre‐Mestre, Nathanaël Lapidus, Olivier Steichen   +8 more
wiley   +1 more source

Random survival forests for the analysis of recurrent events for right-censored data, with or without a terminal event. [PDF]

BMC Med Res Methodol
Murris J, Bouaziz O, Jakubczak M, Katsahian S, Lavenu A.   +4 more
europepmc   +1 more source